Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice
Open Access
- 1 December 2003
- Vol. 52 (12) , 1721-1727
- https://doi.org/10.1136/gut.52.12.1721
Abstract
Background and aims: Multiple rodent models implicate resident intestinal bacteria in the pathogenesis of chronic immune mediated intestinal inflammation. Specific pathogen free (SPF) interleukin 10 gene deficient (IL-10−/−) mice develop colitis, which does not occur in the germ free (GF) state. We investigated whether broad or narrow spectrum antibiotics affect onset and progression of disease in various regions of IL-10−/− mice. Methods: Metronidazole, ciprofloxacin, vancomycin-imipenem (50 mg/kg/day), or water (control) was administered orally before (prevention) or two weeks after (treatment) colonisation of GF IL-10−/− mice with SPF bacteria. After four weeks, colonic histology scores and cytokine production by colonic explants were determined. Caecal and colonic contents were collected for quantitative bacterial analysis. Results: In the prevention study, all antibiotics decreased inflammation in the caecum and colon. However, in the treatment study, ciprofloxacin and vancomycin-imipenem decreased caecal inflammation, and reduced Escherichia coli and Enterococcus faecalis concentrations, whereas only vancomycin-imipenem lowered direct microscopic bacterial counts. In contrast, metronidazole and vancomycin-imipenem reduced colonic injury and eliminated anaerobic bacteria, including Bacteroides spp. Conclusions: Both narrow and broad spectrum antibiotics can prevent disease but treatment of established colitis is more selective. Ciprofloxacin is most effective in the treatment of caecal inflammation, metronidazole preferentially treats the colon, whereas vancomycin-imipenem definitively treats both regions. These results suggest that subsets of aerobic or anaerobic bacteria show regional differences in their capacity to mediate experimental colitis in IL-10−/− mice.Keywords
This publication has 38 references indexed in Scilit:
- Rabeprazole 20 Mg once daily in the treatment of 5024 patients with symptomatic gastroesophageal reflux diseaseGastroenterology, 2001
- Helicobacter hepaticusDoes Not Induce or Potentiate Colitis in Interleukin-10-Deficient MiceInfection and Immunity, 2000
- Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strainGut, 1998
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.Journal of Clinical Investigation, 1996
- The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.The Journal of Experimental Medicine, 1994
- Is There a Role for Antibiotics as Primary Therapy in Crohnʼs Ileitis?Journal of Clinical Gastroenterology, 1993
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993
- The intestinal and serum humoral immune response of mice to systemically and orally administered antigens in liposomes: I. The response to liposome-entrapped soluble proteinsVeterinary Immunology and Immunopathology, 1992
- Double blind, placebo controlled trial of metronidazole in Crohn's disease.Gut, 1991
- Clinical Effect of Metronidazole and Sulfasalazine on Crohn's Disease in Relation to Changes in the Fecal FloraScandinavian Journal of Gastroenterology, 1981